News
MEIP
3.260
-2.17%
-0.072
Weekly Report: what happened at MEIP last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at MEIP last week (0408-0412)?
Weekly Report · 04/15 09:49
MEI Pharma Is Maintained at Hold by Stifel
Dow Jones · 04/12 16:00
MEI Pharma Price Target Maintained With a $7.00/Share by Stifel
Dow Jones · 04/12 16:00
Stifel Maintains Hold on MEI Pharma, Maintains $7 Price Target
Benzinga · 04/12 15:49
MEI Pharma shelves plans for a second return of capital
Seeking Alpha · 04/11 18:17
MEI Pharma Aligns On Strategy To Advance Voruciclib And ME-344
MEI Pharma, Inc. Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement. The Company's Board of Directors unanimously agreed on a strategic plan to prioritize clinical development of voruciclib and ME-344. The Board also determined not to proceed with a second return of capital under the October 31, 2023 cooperation agreement.
Benzinga · 04/11 12:06
MEI Pharma Reports Initial Data From Clinical Study Evaluating ME-344 In Combination With Bevacizumab In Relapsed Metastatic Colorectal Cancer Patients
25% of patients in Cohort 1 of the ongoing Phase 1b study of ME-344 in combination with bevacizumab had no disease progression at Week 16. The combination was generally well-tolerated. MEI Pharma to continue to advance the program via development of a new formulation of the drug.
Benzinga · 04/11 12:05
MEI PHARMA INC: PLAN WILL REDUCE SHORT-TERM EXPENDITURES ON ME-344 PROGRAM
Reuters · 04/11 12:02
MEI PHARMA INC: ME-344 IN COMBINATION WITH BEVACIZUMAB WAS GENERALLY WELL-TOLERATED WITH NO EVIDENCE OF OVERLAPPING TOXICITY
Reuters · 04/11 12:01
Weekly Report: what happened at MEIP last week (0401-0405)?
Weekly Report · 04/08 09:51
Weekly Report: what happened at MEIP last week (0325-0329)?
Weekly Report · 04/01 09:51
Weekly Report: what happened at MEIP last week (0318-0322)?
Weekly Report · 03/25 09:52
Weekly Report: what happened at MEIP last week (0311-0315)?
Weekly Report · 03/18 09:51
Biotech bankruptcies hit a record despite sector’s recovery
Healthcare Biotech bankruptcies hit a record despite sector’s recovery. More biotech firms filed for Chapter 11 bankruptcy than any other year since 2010. In 2023, 18 biotech companies petitioned for court-mediated protection, compared to eight in 2022. The record number of biotech bankruptcies contrasts with the industry's recent gains.
Seeking Alpha · 03/14 18:54
Weekly Report: what happened at MEIP last week (0304-0308)?
Weekly Report · 03/11 09:50
Weekly Report: what happened at MEIP last week (0226-0301)?
Weekly Report · 03/04 09:51
Weekly Report: what happened at MEIP last week (0219-0223)?
Weekly Report · 02/26 09:56
MEI Pharma Announces Flexible $25 Million Funding Strategy
TipRanks · 02/21 21:14
More
Webull provides a variety of real-time MEIP stock news. You can receive the latest news about Mei Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About MEIP
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).